Secondly, CLYF tends to treat liver cancer through the PI3K–Akt signaling pathway, MAPK signaling pathway, hepatitis B signaling pathway, and hepatitis C signaling pathway to exert drug effects. This evidence concerns the gene AKT1 and hepatitis B virus infection.